(MedPage Today) — Faricimab (Vabysmo) showed greater fluid reduction compared with high-dose aflibercept (Eylea) at 12 weeks in matched analyses of diabetic macular edema (DME) and age-related macular degeneration (AMD) studies presented at the…
Source link : https://www.medpagetoday.com/meetingcoverage/arvovideopearls/115798
Author :
Publish date : 2025-05-29 14:23:00
Copyright for syndicated content belongs to the linked Source.
